Source comparison
Melanotan-2 Sunless Tanning Complete Guide 2026: Peptide Comparison
Understanding how melanotan-2 differs from related compounds and alternatives clarifies its risk-benefit position in 2026. Melanotan-2 MC1R/MC3R/MC4R agonist Systemic pigmentation independent of UV Nausea (40–70%), flushing (20–30%), libido changes (30%), dark
This comparison does not assign a generated winner or score.
- Understanding how melanotan-2 differs from related compounds and alternatives clarifies its risk-benefit position in 2026.
- Melanotan-2
- MC1R/MC3R/MC4R agonist
- Systemic pigmentation independent of UV
- Nausea (40–70%), flushing (20–30%), libido changes (30%), darkened moles (universal)
- Not FDA-approved; unregulated consumer use
- Produces reliable tanning but systemic receptor activation causes predictable adverse effects. Requires precise dosing and medical oversight
- Melanotan-1 (afamelanotide)
- Selective MC1R agonist
- UV-independent tanning with fewer systemic effects
- Nausea (10–20%), injection site reaction, headache
- FDA-approved for erythropoietic protoporphyria only
- Safer receptor selectivity profile than MT-2 but unavailable outside clinical settings. Approved formulation is a slow-release implant, not injectable
- Dihydroxyacetone (DHA) topical
- Chemical reaction with skin amino acids
- Surface-level pigmentation, no melanin production
- Uneven colour, orange cast, skin dryness
- FDA-approved as cosmetic colorant
- No systemic effects but purely cosmetic. Washes off in 5–7 days and provides zero UV protection
- UV tanning (natural or bed)
- Direct DNA damage triggers melanin synthesis
- Melanocyte activation via UV radiation
- Photoaging, DNA damage, melanoma risk (dose-dependent)
- Legal but carries known carcinogenic risk
- Produces genuine melanin but through a mechanism that damages DNA. Long-term cancer risk is well-established